Oncologist-approved cancer information from the American Society of Clinical Oncology
Printer Friendly
Download PDF

Leukemia - Acute Lymphoblastic - ALL - Childhood

This section has been reviewed and approved by the Cancer.Net Editorial Board, 11/2012
Classification

Languages

While there is no staging system for childhood ALL compared to other types of cancer, there are a number of factors that help doctors choose the best treatment plan and predict the chance that the disease will come back after treatment. Doctors plan the child’s treatment based on these and other factors:

Age. Infants younger than 12 months and children age 10 and older need more intensive treatments.

White blood cell counts. Children with higher white blood cell counts need more intensive treatments. Commonly, white blood cell counts are labeled as higher if they are more than 50,000 per microliter (ml). 

Immunophenotyping. This test shows the types and amounts of proteins produced (called expressed) by the leukemia cells. Knowing if the cancer cells express the proteins more like those of normal white blood cells called B-cells or T-cells will help doctors plan appropriate treatment and is useful to help predict how well treatment will work.

Genetic abnormalities in the leukemia cells. Abnormal numbers of chromosomes, abnormal structural changes in a chromosome, or certain molecular genetic changes in the chromosomes of leukemia cells may affect outcome and treatment. Note that the genetic changes referred to here are changes in the genes of the leukemia cells, not the child’s cells--most children with leukemia have completely normal genes.

Response to early treatment. How well treatment works in the first one to four weeks of treatment (determined by examining the child’s blood or bone marrow) may predict the disease’s overall response to treatment. Recent studies have shown that some children may need more intense treatment to improve the chance of a cure. This includes children whose cancer is not responding well to early treatment or those who have high levels of residual leukemia cells (cells remaining after treatment) at the end of remission induction (see Treatment).

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: